Radiobiology

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.

As Schools Prepare to Reopen, Experts Recommend Investing in Cleaning and Health Measures - and Violet Defense Has the Products to Support Them

Retrieved on: 
Tuesday, July 27, 2021

Violet Defense CEO Terrance Berland said UV disinfection can help schools and families return to some sense of normalcy this fall.

Key Points: 
  • Violet Defense CEO Terrance Berland said UV disinfection can help schools and families return to some sense of normalcy this fall.
  • Schools are now preparing for safe re-opening, with federal funding supporting measures including cleaning and safety.
  • Another $122.7 billion was approved in March, bringing the total available funds to help defray infrastructure costs to $190.5 billion.
  • Violet Defense UV disinfection products provide regular disinfection while allowing schools to rely less on chemical disinfection protocols.

Aerapy® a Winner in ACHR News 2021 Dealer Design Awards

Retrieved on: 
Tuesday, July 27, 2021

SAINT CHARLES,Ill., July 27, 2021 /PRNewswire/ --Aerapy, a leading manufacturer of ultraviolet germicidal irradiation (UVGI or UV) products, was recognized for excellence in product design in the 18th annual Dealer Design Awards, sponsored by The Air Conditioning, Heating & Refrigeration (ACHR) News magazine, the leading trade magazine for the heating, ventilating, air conditioning, and refrigeration (HVACR) industries.

Key Points: 
  • SAINT CHARLES,Ill., July 27, 2021 /PRNewswire/ --Aerapy, a leading manufacturer of ultraviolet germicidal irradiation (UVGI or UV) products, was recognized for excellence in product design in the 18th annual Dealer Design Awards, sponsored by The Air Conditioning, Heating & Refrigeration (ACHR) News magazine, the leading trade magazine for the heating, ventilating, air conditioning, and refrigeration (HVACR) industries.
  • "Our company started in 2008 with a passion to improve indoor air quality through researched, tested, and study-backed UV products," said Annette Uda, founder and president of Aerapy.
  • "We are beyond proud to have our commitment to creating innovative and effective UV products like the Zone360X recognized by HVACR industry leaders."
  • Winners in the Dealer Design Awards are featured in the July 26, 2021, issue of The ACHR News which is distributed nationally to over 27,000 HVACR contractors, wholesalers and distributors, and other industry professionals.

David K. Roemer, PhD, Celebrated for Excellence in Education and Theology

Retrieved on: 
Monday, July 26, 2021

Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Key Points: 
  • Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
  • In 1972, he was recruited by Litton Medical Systems as a manager of radiation therapy products.
  • Throughout the following five years, he provided technical and sale support for radiation therapy equipment that had been manufactured by Toshiba Corporation.
  • While working for Siemens AG, he completed his education by earning a Master of Business Administration from Pace University's Lubin School of Business.

Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac

Retrieved on: 
Friday, July 23, 2021

ATLANTA, July 23, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of 36 abstracts demonstrating the technical capabilities and clinical utility of the Elekta Unity MR-Linac. The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system. The abstracts are being reported at the 63rd Annual Meeting & Exhibition of the American Association of Physicists in Medicine (AAPM), which is being held virtually July 25-29, 2021."The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta. "These abstracts also reflect the power of the Elekta MR-Linac Consortium,  which played a critical role in developing the technology behind  the first high-field MR-Linac,  to generate robust data that drives evidence-based clinical decision making. We continue to expand the Consortium to build the collection of data from around the world and make advanced radiation medicine available to all cancer patients, regardless of where they are treated."

Key Points: 
  • The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.
  • "The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta.
  • Mr. Brown highlighted several abstracts that exemplify the benefits that Elekta Unity can provide to patients and care centers.
  • This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity.

Data from 14 leading cancer centers presented at AAPM highlight global adoption of Elekta Unity MR-Linac

Retrieved on: 
Friday, July 23, 2021

The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.

Key Points: 
  • The research described in the abstracts was conducted at 14 leading cancer centers in North America, Europe, Asia and Australia, reflecting the broad global adoption of the system.
  • "The Elekta Unity data presented at AAPM clearly validate the benefits of its scan, plan and treat capabilities to enable personalized radiation therapy," said Kevin Brown, Distinguished Scientist at Elekta.
  • Mr. Brown highlighted several abstracts that exemplify the benefits that Elekta Unity can provide to patients and care centers.
  • This abstract describes data from a patient with an intramuscular tumor treated with MR-guided radiation therapy (MRgRT) using Elekta Unity.

DefenderShield Announces the Launch of Ultra Armor™ Technology, the Most Effective 5G and EMF Radiation Shielding Developed to Date

Retrieved on: 
Thursday, July 22, 2021

The extended use of mobile electronic devices and their close proximity to our bodies exposes us to increased levels of Electromagnetic Field (EMF) radiation.

Key Points: 
  • The extended use of mobile electronic devices and their close proximity to our bodies exposes us to increased levels of Electromagnetic Field (EMF) radiation.
  • In the industry, DefenderShield is known as the trusted expert in EMF shielding and education.
  • DefenderShield technology reduces your exposure to Electromagnetic Radiation (EMF) emitted by mobile devices like laptops, tablets, and cell phones.
  • Backed by scientific lab testing, DefenderShield technology blocks up to 99.99% of EMF radiation, including the entire 5G wireless network.

Global Disinfection Robots Market (2021 to 2026) - Evolution of Automated Guided Vehicles & Mobile Robots Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021

The global disinfection robots market by revenue is expected to grow at a CAGR of over 30.69% during the period 2020-2026.

Key Points: 
  • The global disinfection robots market by revenue is expected to grow at a CAGR of over 30.69% during the period 2020-2026.
  • Europe dominated the disinfection robots market share in 2020, followed by North America, APAC, Latin America and the Middle East and Africa.
  • The following factors are likely to contribute to the growth of the disinfection robots market during the forecast period:
    The study considers the global disinfection robots market's present scenario and its market dynamics for the period 2021-2026.
  • UV disinfection has several advantages compared to other cleaning methods and is gaining high traction in the global disinfection robots market.

TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)

Retrieved on: 
Thursday, July 22, 2021

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221.

Key Points: 
  • TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing pipeline of investigational therapies, it has identified several proprietary drug candidates, including TC220 and TC221.
  • Most BNCT clinical studies to date have been carried out using boronophenylalanine (BPA) as the boron target drug.
  • When neutron radiation is applied, the boron atoms react to generate alpha particles that destroy cancer cells.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging

Retrieved on: 
Thursday, July 22, 2021

SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced todaythat the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact System, the next-generation TomoTherapy platform, with ClearRT helical fan-beam kVCT imaging.

Key Points: 
  • SUNNYVALE, Calif., July 22, 2021 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced todaythat the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact System, the next-generation TomoTherapy platform, with ClearRT helical fan-beam kVCT imaging.
  • With the installation of ClearRT the team has raised the bar for other hospitals using radiation therapy as an option in cancer care.
  • The treatment region included the oral cavity and neck lymph nodes, so minimizing dose to nearby critical organs was crucial.
  • "The HKSH team is excited to expand on the Radixact System's capabilities with the addition of the ClearRT imaging technology.